SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
Monaldi Arch Chest Dis
; 90(4)2020 Dec 23.
Article
in English
| MEDLINE | ID: covidwho-1042105
ABSTRACT
We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Respiratory Tract Infections
/
Ritonavir
/
Cystic Fibrosis
/
Lopinavir
/
Antibodies, Monoclonal, Humanized
/
SARS-CoV-2
/
COVID-19
/
COVID-19 Drug Treatment
/
Hydroxychloroquine
Type of study:
Case report
/
Diagnostic study
/
Experimental Studies
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Adult
/
Humans
/
Male
Language:
English
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS